# Patient‐ and caregiver‐reported barriers to chemotherapy in nine sub‐Saharan African countries: A cross‐sectional survey among population‐based registries

**Authors:** Tamara König, Nikolaus Christian Simon Mezger, Ole Stoeter, Phoebe Mary Amulen, Margaret Borok, Gladys C. Chesumbai, Moudiongui MBoungou Dimitry, Ima‐Obong Ekanem, Adugna Fekadu, Bakarou Kamaté, William Muller, Alex Alain Kabena Nzambikolo, Abidemi Omonisi, Furaha Serventi, Markus Wallwiener, Biying Liu, Donald Maxwell Parkin, Pablo Sandro Carvalho Santos, Eva Johanna Kantelhardt, Eric Sven Kroeber

PMC · DOI: 10.1002/ijc.70309 · International Journal of Cancer · 2025-12-30

## TL;DR

This study identifies key barriers to chemotherapy in nine Sub-Saharan African countries, including cost, fear, and lack of knowledge, and suggests region-specific strategies to improve access.

## Contribution

The study provides new insights into chemotherapy barriers in SSA by analyzing patient-reported data across multiple countries and linking them to socioeconomic and national development factors.

## Key findings

- Financial constraints, fear, and lack of knowledge were major barriers to chemotherapy in Sub-Saharan Africa.
- Educational level, self-reported wealth, and national human development index were consistently associated with reported barriers.
- A higher human development index correlated with increased probability of receiving chemotherapy.

## Abstract

Chemotherapy is an essential component of cancer treatment, as outlined in the National Comprehensive Cancer Network (NCCN) guidelines for Sub‐Saharan Africa (SSA). Lack of access to treatment is a key driver of impaired survival rates. This study assessed patient‐perceived barriers to chemotherapy in SSA according to the five dimensions of access to care: availability, accessibility, accommodation, affordability, and acceptability. Telephone interviews were conducted with 553 randomly selected cancer patients (or caretakers), registered between 2018 and 2019 in 11 urban population‐based cancer registries across nine countries in SSA. Malignancy types included breast, cervical, prostate, and colorectal cancer; non‐Hodgkin lymphoma; and Kaposi sarcoma. Patients rated barriers using a 3‐point Likert scale. Barriers to chemotherapy and their associations with patient characteristics were analysed using multivariate ordinal regression analysis. Major barriers included accessibility (cost of transport), affordability (cost of treatment, being absent from home), and acceptability (lack of knowledge/awareness and fear of treatment). Results varied between countries: affordability was especially severe in the Republic of Congo, while in Gabon, fear of treatment prevailed. Knowledge and awareness were particularly concerning in Ethiopia and Zimbabwe. A combined educational level and self‐reported wealth variable, and national human development index (HDI) were consistently associated with reported barriers. Overall, 58.6% of participants received chemotherapy, while 13.2% were recommended chemotherapy but did not receive it. A higher HDI correlated with an increased probability of receiving treatment. A complex set of barriers influenced patients' non‐receipt of treatment. Regionally adapted strategies, including psychosocial support, financial assistance for vulnerable groups, and education, are essential to improve treatment uptake in SSA.

Increasing cancer incidence and mortality in low‐ and middle‐income countries has heightened concerns about limited resources and barriers to care. This challenge is particularly urgent in Sub‐Saharan Africa (SSA), where cancer rates are rising sharply. Here, data from population‐based cancer registries in nine SSA countries was assessed to better understand patient‐reported barriers to chemotherapy access. Analyses identified financial constraints, fear, and limited knowledge and awareness as substantial barriers. Educational level, self‐reported wealth, and national human development index were consistently linked to reported barriers. The findings underscore the need to address socioeconomic inequalities and treatment‐related concerns to ensure fair chemotherapy access in SSA.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989), cervical cancer (MONDO:0002974), prostate cancer (MONDO:0005159), colorectal cancer (MONDO:0005575), non-Hodgkin lymphoma (MONDO:0018908), Kaposi sarcoma (MONDO:0005055)

## Full-text entities

- **Diseases:** Kaposi sarcoma (MESH:D012514), breast, cervical, prostate, and colorectal cancer (MESH:D015179), non-Hodgkin lymphoma (MESH:D008228), Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12996735/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12996735/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12996735/full.md

---
Source: https://tomesphere.com/paper/PMC12996735